These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16055824)

  • 1. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
    Park S; Ross-Degnan D; Adams AS; Sabin J; Kanavos P; Soumerai SB
    Br J Psychiatry; 2005 Aug; 187():137-42. PubMed ID: 16055824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
    Zhao Z; Namjoshi M; Barber BL; Loosbrock DL; Tunis SL; Zhu B; Breier A
    CNS Drugs; 2004; 18(3):157-64. PubMed ID: 14871159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
    Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
    Kumari V; Ettinger U; Lee SE; Deuschl C; Anilkumar AP; Schmechtig A; Corr PJ; Ffytche DH; Williams SC
    Psychopharmacology (Berl); 2015 Sep; 232(17):3135-47. PubMed ID: 25980483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective prescribing of atypical antipsychotics.
    Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian prescription and extrapyramidal symptoms.
    Grover S; Kulhara P
    Br J Psychiatry; 2006 May; 188():492; author reply 492-3. PubMed ID: 16648544
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
    Ren XS; Huang YH; Lee AF; Miller DR; Qian S; Kazis L
    J Clin Pharm Ther; 2005 Feb; 30(1):65-71. PubMed ID: 15659005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
    Akkaya C; Sarandol A; Cangur S; Kirli S
    Hum Psychopharmacol; 2007 Dec; 22(8):515-28. PubMed ID: 17868197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
    Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.